Brief: FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET
26/03/2025 12:37
March 26 (Reuters) - Exelixis Inc EXEL.O: FDA APPROVES CABOZANTINIB FOR ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH PNET AND EPNET Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))